Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Multicenter, Prospective, Randomized, Placebo-Controlled, Double-blind Dose Escalating Study of Safety, Tolerability and Pharmacodynamics of Zirconium Silicate in Chronic Kidney Disease and Moderate Kidney Dysfunction With Mild Hyperkalemia
Brief Summary: It is hypothesized that zirconium silicate is safe and well tolerated and more effective than placebo (alternative hypothesis) in lowering serum potassium levels in subjects with serum potassium between 5 - 6.0 mmol/l versus no difference between zirconium silicate and placebo (null hypothesis). It is hypothesized that zirconium silicate even up to the top dose of 10g three times a day is well tolerated.


Options:
A: Arm Label: Stratum 1: 8.4 g/d patiromer; Type: EXPERIMENTAL; Interventions: Drug: patiromer, Drug: losartan, Drug: spironolactone | Arm Label: Stratum 1: 16.8 g/d patiromer; Type: EXPERIMENTAL; Interventions: Drug: patiromer, Drug: losartan, Drug: spironolactone | Arm Label: Stratum 1: 25.2 g/d patiromer; Type: EXPERIMENTAL; Interventions: Drug: patiromer, Drug: losartan, Drug: spironolactone | Arm Label: Stratum 2: 16.8 g/d patiromer; Type: EXPERIMENTAL; Interventions: Drug: patiromer, Drug: losartan, Drug: spironolactone | Arm Label: Stratum 2: 25.2 g/d patiromer; Type: EXPERIMENTAL; Interventions: Drug: patiromer, Drug: losartan, Drug: spironolactone | Arm Label: Stratum 2: 33.6 g/d patiromer; Type: EXPERIMENTAL; Interventions: Drug: patiromer, Drug: losartan, Drug: spironolactone | Intervention Type: DRUG; Name: patiromer; Assigned to Arm(s): Stratum 1: 8.4 g/d patiromer | Intervention Type: DRUG; Name: patiromer; Assigned to Arm(s): Stratum 2: 16.8 g/d patiromer | Intervention Type: DRUG; Name: patiromer; Assigned to Arm(s): Stratum 1: 16.8 g/d patiromer | Intervention Type: DRUG; Name: patiromer; Assigned to Arm(s): Stratum 1: 25.2 g/d patiromer | Intervention Type: DRUG; Name: patiromer; Assigned to Arm(s): Stratum 2: 25.2 g/d patiromer | Intervention Type: DRUG; Name: patiromer; Assigned to Arm(s): Stratum 2: 33.6 g/d patiromer | Intervention Type: DRUG; Name: losartan; Assigned to Arm(s): Stratum 1: 16.8 g/d patiromer, Stratum 1: 25.2 g/d patiromer, Stratum 1: 8.4 g/d patiromer, Stratum 2: 16.8 g/d patiromer, Stratum 2: 25.2 g/d patiromer, Stratum 2: 33.6 g/d patiromer | Intervention Type: DRUG; Name: spironolactone; Assigned to Arm(s): Stratum 1: 16.8 g/d patiromer, Stratum 1: 25.2 g/d patiromer, Stratum 1: 8.4 g/d patiromer, Stratum 2: 16.8 g/d patiromer, Stratum 2: 25.2 g/d patiromer, Stratum 2: 33.6 g/d patiromer
B: Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Arm Label: Zirconium silicate (ZS); Type: EXPERIMENTAL; Interventions: Drug: Zirconium silicate (ZS) | Intervention Type: DRUG; Name: Zirconium silicate (ZS); Assigned to Arm(s): Zirconium silicate (ZS) | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
C: Arm Label: Sodium Zirconium Cyclosilicate (ZS) 5g; Type: EXPERIMENTAL; Interventions: Drug: Sodium Zirconium Cyclosilicate (ZS) 5g | Arm Label: Sodium Zirconium Cyclosilicate (ZS) 10g; Type: EXPERIMENTAL; Interventions: Drug: Sodium Zirconium Cyclosilicate (ZS) 10g | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Sodium Zirconium Cyclosilicate (ZS) 5g; Assigned to Arm(s): Sodium Zirconium Cyclosilicate (ZS) 5g | Intervention Type: DRUG; Name: Sodium Zirconium Cyclosilicate (ZS) 10g; Assigned to Arm(s): Sodium Zirconium Cyclosilicate (ZS) 10g | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
D: Arm Label: Group 1 - Dosing Without Food; Type: EXPERIMENTAL; Interventions: Drug: patiromer | Arm Label: Group 2 - Dosing With Food; Type: ACTIVE_COMPARATOR; Interventions: Drug: patiromer | Intervention Type: DRUG; Name: patiromer; Assigned to Arm(s): Group 1 - Dosing Without Food, Group 2 - Dosing With Food

Answer: B